EUVIMEDEUVIMED entdecken
Crossref

Impact of administration route and PEGylation on alpha-1 antitrypsin augmentation therapy

Xiao Liu, Bernard Ucakar, Kevin Vanvarenberg, Etienne Marbaix, Rita Vanbever

Journal of Controlled Release · 2025-06 · 382 · 113643

DOI: 10.1016/j.jconrel.2025.113643 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2025-06. Verfasst von Xiao Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Université catholique de Louvain (UCLouvain), Louvain Drug Research Institute, Advanced Drug Delivery & Biomaterials, Brussels, Belgium. Hauptthemen laut MEDLINE: alpha 1-Antitrypsin, Polyethylene Glycols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Alpha-1 Foundation, Central People's Government of the People's Republic of China Scholarship Programme, China Scholarship Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients suffering from emphysema associated with alpha-1 antitrypsin (AAT) deficiency can benefit from augmentation therapy. AAT is administered to the patient once a week via intravenous infusion by a healthcare professional. However, only 2 % of the AAT dose reaches the lungs following intravenous infusion. Inhalation of AAT might be a convenient and effective alternative to intravenous infusion. Yet, it has shown limited therapeutic efficacy in a recent clinical trial. Here, we assessed the impact of these routes of AAT administration on AAT pharmacokinetics, lung distribution and therapeutic efficacy in mice. PEGylation of the serpin was employed to improve its therapeutic value. Intravenous injection of AAT or its local administration to the lungs resulted in a similar exposure of AAT in the lung parenchyma with however an AAT dose delivered to the lungs 45 times lower than the injected dose. Conjugation of AAT to a 2-armed 40 kDa polyethylene glycol (PEG) chain prolonged its half-life in plasma and lungs by 1.6-times, decreased its penetration in the lung tissue by both routes of administration but did not markedly affect the lung exposure to AAT. The PEG moiety in PEG-AAT was cleared more slowly than the protein moiety and high PEG quantities remained in the lung tissue and alveolar macrophages several days after intratracheal instillation. Pulmonary administration and PEGylation both improved AAT efficacy to prevent lung injury and inflammation in a murine model of chronic obstructive pulmonary disease where lung inflammation was induced by delivering porcine pancreatic elastase and lipopolysaccharide locally to the airways. Anti-AAT and anti-PEG antibodies were generated by AAT and PEG-AAT administration, as expected for a foreign protein. However, anti-PEG antibodies did not significantly contribute to the overall anti-drug antibody titers against the conjugate. AAT and PEG-AAT showed good stability to jet nebulization. This study provides new insights into the impact of administration route and PEGylation on lung exposure, clearance, therapeutic efficacy, and safety of AAT. It highlights that inhalation of AAT might effectively replace its intravenous infusion in augmentation therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

alpha 1-AntitrypsinPolyethylene GlycolsAnimalsMiceLungMaleMice, Inbred C57BLInjections, Intravenousalpha 1-Antitrypsin DeficiencyAdministration, Inhalation

Stichwörter der Autor:innen

Alpha1 antitrypsinAugmentation therapyChronic obstructive pulmonary diseaseInhalationPEGylation

Substanzen

alpha 1-AntitrypsinPolyethylene Glycols

Autor:innen und Institutionen

  • Université catholique de Louvain (UCLouvain), Louvain Drug Research Institute, Advanced Drug Delivery & Biomaterials, Brussels, Belgium.
  • UCLouvain, de Duve Institute, Cell Biology Unit and Cliniques universitaires Saint-Luc, Pathology Department, Brussels, Belgium.
  • Université catholique de Louvain (UCLouvain), Louvain Drug Research Institute, Advanced Drug Delivery & Biomaterials, Brussels, Belgium. Electronic address: rita.vanbever@uclouvain.be.

Förderung

  • Alpha-1 Foundation
  • Central People's Government of the People's Republic of China Scholarship Programme
  • China Scholarship Council
  • Fonds De La Recherche Scientifique - FNRS

Zitieren

APA

Liu, X., Ucakar, B., Vanvarenberg, K., Marbaix, E., & Vanbever, R. (2025). Impact of administration route and PEGylation on alpha-1 antitrypsin augmentation therapy. Journal of Controlled Release, 382, 113643. https://doi.org/10.1016/j.jconrel.2025.113643

Vancouver

Liu X, Ucakar B, Vanvarenberg K, Marbaix E, Vanbever R. Impact of administration route and PEGylation on alpha-1 antitrypsin augmentation therapy. Journal of Controlled Release. 2025;382:113643. doi:10.1016/j.jconrel.2025.113643

BibTeX
@article{Liu2025,
  author = {Liu, Xiao and Ucakar, Bernard and Vanvarenberg, Kevin and Marbaix, Etienne and Vanbever, Rita},
  title = {Impact of administration route and PEGylation on alpha-1 antitrypsin augmentation therapy},
  journal = {Journal of Controlled Release},
  year = {2025},
  volume = {382},
  pages = {113643},
  doi = {10.1016/j.jconrel.2025.113643}
}
Kostenlos starten →